Logo image of JAZZ

JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis

USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock

135.43 USD
-2.72 (-1.97%)
Last: 10/10/2025, 9:36:51 PM
135.43 USD
0 (0%)
After Hours: 10/10/2025, 9:36:51 PM
Fundamental Rating

4

Overall JAZZ gets a fundamental rating of 4 out of 10. We evaluated JAZZ against 196 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. JAZZ may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year JAZZ was profitable.
In the past year JAZZ had a positive cash flow from operations.
In multiple years JAZZ reported negative net income over the last 5 years.
JAZZ had a positive operating cash flow in each of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

JAZZ has a better Return On Assets (-3.70%) than 73.98% of its industry peers.
JAZZ has a Return On Equity of -10.92%. This is in the better half of the industry: JAZZ outperforms 73.47% of its industry peers.
JAZZ has a Return On Invested Capital of 5.47%. This is amongst the best in the industry. JAZZ outperforms 82.65% of its industry peers.
The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 15.30%.
The last Return On Invested Capital (5.47%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -3.7%
ROE -10.92%
ROIC 5.47%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

JAZZ's Profit Margin has declined in the last couple of years.
JAZZ has a better Operating Margin (15.03%) than 85.71% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
JAZZ's Gross Margin of 88.71% is amongst the best of the industry. JAZZ outperforms 91.33% of its industry peers.
JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 15.03%
PM (TTM) N/A
GM 88.71%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so JAZZ is destroying value.
JAZZ has less shares outstanding than it did 1 year ago.
The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
Compared to 1 year ago, JAZZ has a worse debt to assets ratio.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

Based on the Altman-Z score of 1.42, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
JAZZ has a better Altman-Z score (1.42) than 60.71% of its industry peers.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of JAZZ (4.33) is better than 85.20% of its industry peers.
A Debt/Equity ratio of 1.17 is on the high side and indicates that JAZZ has dependencies on debt financing.
JAZZ has a Debt to Equity ratio of 1.17. This is in the lower half of the industry: JAZZ underperforms 75.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 4.33
Altman-Z 1.42
ROIC/WACC0.78
WACC7.02%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

A Current Ratio of 1.62 indicates that JAZZ should not have too much problems paying its short term obligations.
JAZZ has a worse Current ratio (1.62) than 66.33% of its industry peers.
JAZZ has a Quick Ratio of 1.37. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.37, JAZZ is doing worse than 64.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.37
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for JAZZ have decreased strongly by -62.78% in the last year.
JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.47% yearly.
Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.52% in the last year.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%

3.2 Future

Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 6.88% on average per year.
Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 6.33% on average per year.
EPS Next Y-74.63%
EPS Next 2Y2.39%
EPS Next 3Y5.29%
EPS Next 5Y6.88%
Revenue Next Year4.32%
Revenue Next 2Y5.24%
Revenue Next 3Y5.87%
Revenue Next 5Y6.33%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 20.40, which indicates a rather expensive current valuation of JAZZ.
Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 82.65% of the companies are valued more expensively.
JAZZ's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.02.
Based on the Price/Forward Earnings ratio of 6.10, the valuation of JAZZ can be described as very cheap.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaply inside the industry as 94.39% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.57, JAZZ is valued rather cheaply.
Industry RankSector Rank
PE 20.4
Fwd PE 6.1
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

89.80% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 93.88% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.62
EV/EBITDA 9.01
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.73
EPS Next 2Y2.39%
EPS Next 3Y5.29%

More info and screens

0

5. Dividend

5.1 Amount

JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (10/10/2025, 9:36:51 PM)

After market: 135.43 0 (0%)

135.43

-2.72 (-1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners106.51%
Inst Owner Change0%
Ins Owners2.49%
Ins Owner Change0.27%
Market Cap8.22B
Analysts84.8
Price Target190.69 (40.8%)
Short Float %9.02%
Short Ratio7.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.5%
Min EPS beat(2)-64.64%
Max EPS beat(2)-6.35%
EPS beat(4)2
Avg EPS beat(4)-10.46%
Min EPS beat(4)-64.64%
Max EPS beat(4)17.85%
EPS beat(8)3
Avg EPS beat(8)-9.87%
EPS beat(12)4
Avg EPS beat(12)-16.71%
EPS beat(16)7
Avg EPS beat(16)-10.46%
Revenue beat(2)0
Avg Revenue beat(2)-6.37%
Min Revenue beat(2)-10.66%
Max Revenue beat(2)-2.09%
Revenue beat(4)1
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.73%
Revenue beat(12)1
Avg Revenue beat(12)-2.38%
Revenue beat(16)3
Avg Revenue beat(16)-2.09%
PT rev (1m)1.76%
PT rev (3m)-1.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.3%
EPS NY rev (1m)0.47%
EPS NY rev (3m)6.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.32%
Valuation
Industry RankSector Rank
PE 20.4
Fwd PE 6.1
P/S 2.01
P/FCF 6.62
P/OCF 6.24
P/B 2.22
P/tB N/A
EV/EBITDA 9.01
EPS(TTM)6.64
EY4.9%
EPS(NY)22.22
Fwd EY16.4%
FCF(TTM)20.44
FCFY15.09%
OCF(TTM)21.69
OCFY16.02%
SpS67.37
BVpS61.1
TBVpS-47.92
PEG (NY)N/A
PEG (5Y)3.73
Profitability
Industry RankSector Rank
ROA -3.7%
ROE -10.92%
ROCE 6.92%
ROIC 5.47%
ROICexc 6.73%
ROICexgc 82.21%
OM 15.03%
PM (TTM) N/A
GM 88.71%
FCFM 30.34%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexcg growth 3Y32.25%
ROICexcg growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.17
Debt/FCF 4.33
Debt/EBITDA 3.37
Cap/Depr 11.29%
Cap/Sales 1.86%
Interest Coverage 250
Cash Conversion 102.28%
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.37
Altman-Z 1.42
F-Score5
WACC7.02%
ROIC/WACC0.78
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
EPS Next Y-74.63%
EPS Next 2Y2.39%
EPS Next 3Y5.29%
EPS Next 5Y6.88%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
Revenue Next Year4.32%
Revenue Next 2Y5.24%
Revenue Next 3Y5.87%
Revenue Next 5Y6.33%
EBIT growth 1Y-0.29%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-54.85%
EBIT Next 3Y4.81%
EBIT Next 5Y7.57%
FCF growth 1Y25.59%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y-4.47%
OCF growth 3Y21.49%
OCF growth 5Y12.45%